<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650558</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00043360; DAIDS ES-10822</org_study_id>
    <secondary_id>U01AI089342-01A1</secondary_id>
    <nct_id>NCT01650558</nct_id>
  </id_info>
  <brief_title>Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi</brief_title>
  <acronym>TSCQ</acronym>
  <official_title>Randomized, Open-label Controlled Trial of Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on Anti-retroviral Therapy in Malawi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if there is a benefit to taking&#xD;
      trimethoprim-sulfamethoxazole (TS) as prophylaxis among HIV positive adults who have viral&#xD;
      load suppression and a good clinical response on anti-retroviral therapy (ART). If there is a&#xD;
      benefit, then is it due to antimalarial or antibacterial properties.&#xD;
&#xD;
      The investigators hypothesize that there will be a long-term benefit on survival and disease&#xD;
      control in the context of prophylaxis and that the benefit will largely be attributed to&#xD;
      prevention of malaria. The main study hypothesis is that 1)TS and chloroquine (CQ) will&#xD;
      decrease the rates of morbidity and mortality among adults after 6 or more months of ART and&#xD;
      2) CQ prophylaxis will be associated with more prolonged viral suppression and higher CD4&#xD;
      cell counts than TS prophylaxis or no prophylaxis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, open-label, phase III trial of standard of care TS&#xD;
      prophylaxis and CQ prophylaxis compared to no prophylaxis in adults receiving ART. Adults who&#xD;
      have been receiving ART for at least six months with a good clinical response and provide&#xD;
      informed consent and fulfill the eligibility criteria will be randomized to one of three&#xD;
      arms: (1) to continue standard of care trimethoprim-sulfamethoxazole (TS) prophylaxis, (2)&#xD;
      discontinue standard of care TS prophylaxis and begin weekly CQ prophylaxis or (3)&#xD;
      discontinue standard of care TS prophylaxis. Participants will be asked to return to the&#xD;
      research clinic every four weeks for the first 24 weeks then every 12 weeks thereafter, and&#xD;
      any time they are ill to facilitate both active and passive follow-up of the study endpoints.&#xD;
      Participation will last for 32 to approximately 66 months. Participants who develop a WHO&#xD;
      clinical stage 3 or 4 illness, experience a sustained decline in their CD4 count below 200&#xD;
      cells/mm3, or who experience ART failure will be placed on standard of care TS prophylaxis.&#xD;
      Those with confirmed ART failure will be evaluated for second-line therapy according to the&#xD;
      Malawi Ministry of Health guidelines.&#xD;
&#xD;
      The study population will include up to 1500 Malawian adults aged 18 years or older living&#xD;
      with HIV in or near Blantyre or Zomba, Malawi, Central Africa who have been receiving&#xD;
      antiretroviral therapy for at least 6 months with good clinical response to ART, have an&#xD;
      undetectable HIV viral load and a CD4 count &gt;250/mm3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe Events</measure>
    <time_frame>22-66 months</time_frame>
    <description>Incidence of severe events (composite of death and WHO stage 3 and 4 illness)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Detectable HIV Viral Load</measure>
    <time_frame>Throughout study participation, measured every six months (2-5.5 years).</time_frame>
    <description>Number of participants who ever have a detectable viral load (&gt;400 copies/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Every 6 months for 22-66 months</time_frame>
    <description>Number of Participants with at Least One CD4 Count &lt;200</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO HIV Stage 2, 3, 4 Illness</measure>
    <time_frame>32-66 months</time_frame>
    <description>Incidence of any WHO HIV stage 2, 3, or 4 illness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial Infections and Malaria</measure>
    <time_frame>32-66 months</time_frame>
    <description>Incidence of bacterial infections and malaria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Greater Than or Equal to Grade 3 That Are Related to the Study Product</measure>
    <time_frame>32-66 months</time_frame>
    <description>Occurrence of adverse events that are greater than or equal to Grade 3 that require discontinuation of TS or CQ prophylaxis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bacterial or Malaria Infection With CQ or TS Resistant Organism</measure>
    <time_frame>32-66 months</time_frame>
    <description>Occurrence of bacterial or malaria infection with CQ or TS resistant organism</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical and Parasitological Response to Antimalarial Therapy</measure>
    <time_frame>32-66 months</time_frame>
    <description>Clinical and parasitological response to antimalarial therapy in cases of uncomplicated malaria</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1499</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Standard of Care Prophylaxis (TS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine (CQ) prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuation of standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care prophylaxis</intervention_name>
    <description>Daily trimethoprim sulfamethoxazole</description>
    <arm_group_label>Standard of Care Prophylaxis (TS)</arm_group_label>
    <other_name>Bactrim</other_name>
    <other_name>Co-trimoxazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine (CQ) prophylaxis</intervention_name>
    <description>Discontinue standard of care and start weekly CQ.</description>
    <arm_group_label>Chloroquine (CQ) prophylaxis</arm_group_label>
    <other_name>Aralen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Documented HIV-1 infection&#xD;
&#xD;
          -  Initiation of ART through a government-sponsored ART program at least six months prior&#xD;
&#xD;
          -  Undetectable HIV viral load (&lt; 400 copies/mL)&#xD;
&#xD;
          -  CD4 count &gt; 250/mm3&#xD;
&#xD;
          -  TS prophylaxis prescribed for at least the previous 2 months&#xD;
&#xD;
          -  Intention to remain in the study area until the end of the study period&#xD;
&#xD;
          -  Informed consent from participant&#xD;
&#xD;
          -  Female study volunteers of reproductive potential must have a negative urine pregnancy&#xD;
             test performed within 20 days before randomization.&#xD;
&#xD;
          -  Female study volunteers of reproductive potential who participate in sexual activity&#xD;
             that could lead to pregnancy must use contraception (male or female condoms, diaphragm&#xD;
             or cervical cap with spermicide, intrauterine device, or hormone-based contraceptive)&#xD;
             while receiving their assigned study drug and for one month after stopping the&#xD;
             medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe acute illness (defined as requiring hospitalization at the time of screening or&#xD;
             other conditions such as laboratory abnormalities as determined by the investigators)&#xD;
&#xD;
          -  Chronic treatment (requiring therapy for &gt; 14 days) or secondary prophylaxis (for&#xD;
             toxoplasmosis, Pneumocystis pneumonia, or tuberculosis for example) with any drug with&#xD;
             antimalarial or antibacterial activity&#xD;
&#xD;
          -  History of hypersensitivity to antifolate drugs or CQ&#xD;
&#xD;
          -  Laboratory exclusion criteria&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 gm/dL&#xD;
&#xD;
          -  Platelet count &lt; 50,000/mm3&#xD;
&#xD;
          -  Absolute granulocyte count &lt; 500/mm3&#xD;
&#xD;
          -  Serum alanine aminotransferase (ALT) concentration &gt; 210 U/L for men, &gt;160 U/L for&#xD;
             women&#xD;
&#xD;
          -  Serum creatinine concentration &gt; 3.3mg/dl (291.7µmol/L) for men, and &gt; 2.7mg/dl&#xD;
             (238.7µmol/L) for women)&#xD;
&#xD;
          -  History of visual field or retinal changes&#xD;
&#xD;
          -  History of preexisting auditory damage&#xD;
&#xD;
          -  History of porphyria&#xD;
&#xD;
          -  History of psoriasis&#xD;
&#xD;
          -  History of liver disease&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  History of glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  History of ECG and cardiac conduction abnormality or cardiomyopathy&#xD;
&#xD;
          -  History of myopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam K Laufer, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blantyre Malaria Project Research Clinic</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tisungane Clinic</name>
      <address>
        <city>Zomba</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <reference>
    <citation>Laurens MB, Mungwira RG, Nampota N, Nyirenda OM, Divala TH, Kanjala M, Mkandawire FA, Galileya LT, Nyangulu W, Mwinjiwa E, Downs M, Tillman A, Taylor TE, Mallewa J, Plowe CV, van Oosterhout JJ, Laufer MK. Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial. Clin Infect Dis. 2021 Sep 15;73(6):1058-1065. doi: 10.1093/cid/ciab252.</citation>
    <PMID>33744963</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 6, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <results_first_submitted>August 22, 2019</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, College Park</investigator_affiliation>
    <investigator_full_name>Miriam Laufer</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>HIV</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT01650558/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis</title>
          <description>Participants will continue standard of care daily TS prophylaxis (two tablets each of 80 mg trimethoprim and 400 mg sulfamethoxazole or one tablet each of 160 mg trimethoprim and 800 mg sulfamethoxazole).</description>
        </group>
        <group group_id="P2">
          <title>Chloroquine (CQ) Prophylaxis</title>
          <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and start weekly CQ prophylaxis at 300 mg.</description>
        </group>
        <group group_id="P3">
          <title>Discontinuation of Standard of Care (Control Arm)</title>
          <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and receive no prophylaxis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="500"/>
                <participants group_id="P3" count="499"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="417"/>
                <participants group_id="P2" count="408"/>
                <participants group_id="P3" count="424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Migration out of study area</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant participant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis</title>
          <description>Participants will continue standard of care daily TS prophylaxis (two tablets each of 80 mg trimethoprim and 400 mg sulfamethoxazole or one tablet each of 160 mg trimethoprim and 800 mg sulfamethoxazole).</description>
        </group>
        <group group_id="B2">
          <title>Chloroquine (CQ) Prophylaxis</title>
          <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and start weekly CQ prophylaxis at 300 mg..</description>
        </group>
        <group group_id="B3">
          <title>Discontinuation of Standard of Care (Control Arm)</title>
          <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and receive no prophylaxis.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="500"/>
            <count group_id="B2" value="500"/>
            <count group_id="B3" value="499"/>
            <count group_id="B4" value="1499"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="494"/>
                    <measurement group_id="B2" value="496"/>
                    <measurement group_id="B3" value="480"/>
                    <measurement group_id="B4" value="1470"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="9.7"/>
                    <measurement group_id="B2" value="38.7" spread="9.6"/>
                    <measurement group_id="B3" value="39.4" spread="10.1"/>
                    <measurement group_id="B4" value="39.1" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="375"/>
                    <measurement group_id="B2" value="374"/>
                    <measurement group_id="B3" value="386"/>
                    <measurement group_id="B4" value="1135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="500"/>
                    <measurement group_id="B3" value="499"/>
                    <measurement group_id="B4" value="1499"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="500"/>
                    <measurement group_id="B3" value="499"/>
                    <measurement group_id="B4" value="1499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severe Events</title>
        <description>Incidence of severe events (composite of death and WHO stage 3 and 4 illness)</description>
        <time_frame>22-66 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis</title>
            <description>Participants will continue standard of care daily TS prophylaxis (two tablets each of 80 mg trimethoprim and 400 mg sulfamethoxazole or one tablet each of 160 mg trimethoprim and 800 mg sulfamethoxazole).</description>
          </group>
          <group group_id="O2">
            <title>Chloroquine (CQ) Prophylaxis</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and start weekly CQ prophylaxis at 300 mg.</description>
          </group>
          <group group_id="O3">
            <title>Discontinuation of Standard of Care (Control Arm)</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and receive no prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Events</title>
          <description>Incidence of severe events (composite of death and WHO stage 3 and 4 illness)</description>
          <units>Events per 100 participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>P-Value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Poisson</method>
            <method_desc>Rate ratio confidence intervals and p-values were adjusted for overdispersion using the Pearson's chi-square scale.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>P-Value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Poisson</method>
            <method_desc>Rate ratio confidence intervals and p-values were adjusted for overdispersion using the Pearson's chi-square scale.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Detectable HIV Viral Load</title>
        <description>Number of participants who ever have a detectable viral load (&gt;400 copies/ml).</description>
        <time_frame>Throughout study participation, measured every six months (2-5.5 years).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis</title>
            <description>Participants will continue standard of care daily TS prophylaxis (two tablets each of 80 mg trimethoprim and 400 mg sulfamethoxazole or one tablet each of 160 mg trimethoprim and 800 mg sulfamethoxazole).</description>
          </group>
          <group group_id="O2">
            <title>Chloroquine (CQ) Prophylaxis</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and start weekly CQ prophylaxis at 300 mg.</description>
          </group>
          <group group_id="O3">
            <title>Discontinuation of Standard of Care (Control Arm)</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and receive no prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Detectable HIV Viral Load</title>
          <description>Number of participants who ever have a detectable viral load (&gt;400 copies/ml).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>No adjustment for multiple comparisons was made.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Cell Count</title>
        <description>Number of Participants with at Least One CD4 Count &lt;200</description>
        <time_frame>Every 6 months for 22-66 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis</title>
            <description>Participants will continue standard of care daily TS prophylaxis (two tablets each of 80 mg trimethoprim and 400 mg sulfamethoxazole or one tablet each of 160 mg trimethoprim and 800 mg sulfamethoxazole).</description>
          </group>
          <group group_id="O2">
            <title>Chloroquine (CQ) Prophylaxis</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and start weekly CQ prophylaxis at 300 mg.</description>
          </group>
          <group group_id="O3">
            <title>Discontinuation of Standard of Care (Control Arm)</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and receive no prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>Number of Participants with at Least One CD4 Count &lt;200</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WHO HIV Stage 2, 3, 4 Illness</title>
        <description>Incidence of any WHO HIV stage 2, 3, or 4 illness</description>
        <time_frame>32-66 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis</title>
            <description>Participants will continue standard of care daily TS prophylaxis (two tablets each of 80 mg trimethoprim and 400 mg sulfamethoxazole or one tablet each of 160 mg trimethoprim and 800 mg sulfamethoxazole).</description>
          </group>
          <group group_id="O2">
            <title>Chloroquine (CQ) Prophylaxis</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and start weekly CQ prophylaxis at 300 mg.</description>
          </group>
          <group group_id="O3">
            <title>Discontinuation of Standard of Care (Control Arm)</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and receive no prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>WHO HIV Stage 2, 3, 4 Illness</title>
          <description>Incidence of any WHO HIV stage 2, 3, or 4 illness</description>
          <units>Events per 100 participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="5.7"/>
                    <measurement group_id="O3" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Poisson</method>
            <method_desc>Rate ratio confidence intervals and p-values were adjusted for overdispersion using the Pearson's chi-square scale.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Poisson</method>
            <method_desc>Rate ratio confidence intervals and p-values were adjusted for overdispersion using the Pearson's chi-square scale.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bacterial Infections and Malaria</title>
        <description>Incidence of bacterial infections and malaria</description>
        <time_frame>32-66 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis</title>
            <description>Participants will continue standard of care daily TS prophylaxis (two tablets each of 80 mg trimethoprim and 400 mg sulfamethoxazole or one tablet each of 160 mg trimethoprim and 800 mg sulfamethoxazole).</description>
          </group>
          <group group_id="O2">
            <title>Chloroquine (CQ) Prophylaxis</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and start weekly CQ prophylaxis at 300 mg.</description>
          </group>
          <group group_id="O3">
            <title>Discontinuation of Standard of Care (Control Arm)</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and receive no prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacterial Infections and Malaria</title>
          <description>Incidence of bacterial infections and malaria</description>
          <units>Events per 100 participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="37.4"/>
                    <measurement group_id="O3" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Poisson</method>
            <method_desc>Rate ratio confidence intervals and p-values were adjusted for overdispersion using the Pearson's chi-square scale.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Will assess performance of each experimental group relative to TS with a noninferiority margin for 1-HR of 0.35 to test the null (1-HR ≥ 0.35) and alternative (1-HR &lt; 0.35) hypotheses. Each experimental group will be declared noninferior to TS if the upper bound of the 95% confidence interval of 1-HR is below 0.35. For ease of interpretation, the HRs have been recast with TS as the reference group, such that HRs greater than 1 indicate an increase in the experimental hazard rate relative to TS.</non_inferiority_desc>
            <p_value>&lt;=0.05</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Poisson</method>
            <method_desc>Rate ratio confidence intervals and p-values were adjusted for overdispersion using the Pearson's chi-square scale.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events Greater Than or Equal to Grade 3 That Are Related to the Study Product</title>
        <description>Occurrence of adverse events that are greater than or equal to Grade 3 that require discontinuation of TS or CQ prophylaxis</description>
        <time_frame>32-66 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis</title>
            <description>Participants will continue standard of care daily TS prophylaxis (two tablets each of 80 mg trimethoprim and 400 mg sulfamethoxazole or one tablet each of 160 mg trimethoprim and 800 mg sulfamethoxazole).</description>
          </group>
          <group group_id="O2">
            <title>Chloroquine (CQ) Prophylaxis</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and start weekly CQ prophylaxis at 300 mg..</description>
          </group>
          <group group_id="O3">
            <title>Discontinuation of Standard of Care (Control Arm)</title>
            <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and receive no prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Greater Than or Equal to Grade 3 That Are Related to the Study Product</title>
          <description>Occurrence of adverse events that are greater than or equal to Grade 3 that require discontinuation of TS or CQ prophylaxis</description>
          <units>Events per 100 participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.24"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Bacterial or Malaria Infection With CQ or TS Resistant Organism</title>
        <description>Occurrence of bacterial or malaria infection with CQ or TS resistant organism</description>
        <time_frame>32-66 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical and Parasitological Response to Antimalarial Therapy</title>
        <description>Clinical and parasitological response to antimalarial therapy in cases of uncomplicated malaria</description>
        <time_frame>32-66 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 to 5.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care Trimethoprim Sulfamethoxazo (TS) Prophylaxis</title>
          <description>Participants will continue standard of care daily TS prophylaxis (two tablets each of 80 mg trimethoprim and 400 mg sulfamethoxazole or one tablet each of 160 mg trimethoprim and 800 mg sulfamethoxazole).</description>
        </group>
        <group group_id="E2">
          <title>Chloroquine (CQ) Prophylaxis</title>
          <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and start weekly CQ prophylaxis at 300 mg.</description>
        </group>
        <group group_id="E3">
          <title>Discontinuation of Standard of Care (Control Arm)</title>
          <description>Participants will discontinue standard of care trimethoprim sulfamethoxazol prophylaxis and receive no prophylaxis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="500"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="500"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="500"/>
                <counts group_id="E3" events="48" subjects_affected="40" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injuries</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="500"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="500"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, puerperium and perinatal</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="500"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="500"/>
                <counts group_id="E3" events="32" subjects_affected="29" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="488" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="483" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="488" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood</sub_title>
                <counts group_id="E1" subjects_affected="240" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="205" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial and genetic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="248" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="291" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" subjects_affected="304" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="267" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="312" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" subjects_affected="414" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="428" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="443" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injuries</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="298" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="307" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="278" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="264" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="224" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, puerperium and perinatal</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="138" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Miriam K. Laufer, M.D., M.P.H.</name_or_title>
      <organization>University of Maryland School of Medicine</organization>
      <phone>410-706-5333</phone>
      <email>mlaufer@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

